Drug Profile
ALRN 5281
Alternative Names: ALRN-5281Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Aileron Therapeutics
- Class Peptides
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lipodystrophy; Somatotropin deficiency
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Lipodystrophy(In volunteers) in USA (SC, Injection)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Somatotropin-deficiency(In volunteers) in USA (SC, Injection)
- 14 Apr 2016 Phase I development is ongoing in USA